Medicine and Dentistry
Patient
100%
Multiple Sclerosis
87%
COVID-19
46%
Therapeutic Procedure
35%
Combination Therapy
32%
Myositis
21%
Muscle
21%
Infection
19%
Magnetic Resonance Imaging
19%
Symptom
19%
Diseases
17%
Fumaric Acid Dimethyl Ester
16%
Follow up
14%
Association
14%
Severe Acute Respiratory Syndrome Coronavirus 2
14%
Alemtuzumab
14%
Lymphocytopenia
13%
Onset Age
13%
Inpatient
13%
Diagnosis
13%
Analysis
12%
Complication
12%
Odds Ratio
11%
Cells
11%
Lesion
11%
CD20
10%
Prevalence
10%
Autoimmunity
10%
Case Report
9%
Neurologic Disease
9%
Ocrelizumab
9%
Methylprednisolone
8%
Outpatient
8%
Antibody
8%
Liver Injury
8%
Oculopharyngeal Muscular Dystrophy
8%
Valerian
8%
Cyclophosphamide
8%
Ixekizumab
8%
Epidermal Growth Factor Receptor
8%
Demyelination
8%
Thyroid Gland
8%
Upper Limb
8%
Haplotype
8%
Lymphocyte
8%
Fingolimod
8%
Drug
8%
Chemotherapeutic Agent
8%
Recurrent Disease
7%
Surgery
7%
Neuroscience
Multiple Sclerosis
88%
Ocrelizumab
31%
Relapsing Remitting Multiple Sclerosis
22%
Long Non-Coding RNA
20%
Amyotrophic Lateral Sclerosis
16%
Transverse Myelitis
16%
Magnetic Resonance Imaging
15%
Myelitis
14%
Antibodies
13%
Differential Diagnosis
12%
Chitinase
12%
Muscle Disorder
12%
Magnetic Resonance Imaging
11%
Sarcoidosis
10%
Osteopontin
9%
MicroRNA
9%
Natalizumab
8%
Rituximab
8%
Cladribine
8%
Untranslated Region
8%
Teriflunomide
8%
Phenotype
8%
Acute Disseminated Encephalomyelitis
8%
Alpha Blocker
8%
Tumor Necrosis Factor Alpha
8%
Ixekizumab
8%
Coronavirus
8%
Methylation
8%
Myositis
8%
Circulating microRNA
8%
HLA-DRB1
8%
Haplotype
8%
Fingolimod
8%
Natalizumab
8%
Gene
6%
Fingolimod
6%
Promoter Region
6%
Interferon
6%
Expanded Disability Status Scale
5%
Myelin Basic Protein
5%
Lymph Node
5%
Computed Tomography
5%
Ependymoma
5%
CD20
5%
Immunology and Microbiology
Multiple Sclerosis
65%
Ocrelizumab
21%
COVID-19
21%
Liquid
17%
Muscle
14%
Monospecific Antibody
13%
Osteopontin
12%
Electric Potential
12%
Cells
11%
Vaccine Efficacy
10%
CD20
9%
Severe Acute Respiratory Syndrome Coronavirus 2
9%
Inclusion Body Myositis
9%
Time
8%
Phenotype
8%
Fingolimod
8%
CD44
8%
Autoimmune Disease
8%
Tumor Necrosis Factor Alpha
8%
CD4
8%
Humoral Immunity
8%
Macrophage
8%
Haplotype
8%
Fumaric Acid Dimethyl Ester
8%
B Cell Activating Factor
7%
Rituximab
6%
Natalizumab
6%
Modulation
6%
Prevalence
5%
CXCL13
5%
CHI3L1
5%
Myelin
5%
Myelin
5%
TLR2
5%
T Helper Cell
5%
Dynamics
5%
Lymphocyte Subpopulation
5%
Age
5%
